HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: JOE-08-0479v1 JOE-08-0479v2 201/1/115    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Galsgaard, E. D. Articles by Panina, S. Search for Related Content PubMed PubMed Citation Articles by Galsgaard, E. D. Articles by Panina, S.

¹ Biopharmaceutical Research Unit, Novo Nordisk A/S, Novo Nordisk Park, Maaloev DK-2760, Denmark² Nordsjaellands Hospital, Helsevej 2, Hilleroed DK-3400, Denmark³ Department of Biology, University of Copenhagen, Ole Maaløes Vej, Copenhagen DK-2200, Denmark

(Correspondence should be addressed to S Panina; Email: svt{at}novonordisk.com)

The pituitary hormone PRL is involved in tumorigenesis in rodents and humans. PRL promotes proliferation, survival and migration of cancer cells acting via the PRL receptor (PRLR). Aiming to perform a large-scale immunohistochemical (IHC) screening of human mammary carcinomas for PRLR expression, we evaluated the specificity of commercially available anti-human PRLR antibodies (B6.2, U5, PRLRi pAb, 1A2B1, 250448 and H-300). The latter three antibodies were found to specifically recognise PRLR. The relative PRLR expression level detected with these antibodies closely reflected the level of ¹²⁵I-PRL binding to the cell surface. The monoclonal antibody (mAb) 250448 was specific for the N-glycosylated form of PRLR and blocked PRL binding and signalling. The PRLRi polyclonal antibody recognised cytokeratin-18. The mAb B6.2, previously used in a number of studies, was found to lack specificity for PRLR and to rather recognise a PRLR-associated protein. The mAb U5 raised against the rat PRLR did not cross-react with the human receptor. Only one mAb, 1A2B1, was found useful for detection of PRLR in IHC applications. This antibody recognised PRLR expressed in human breast cancer cell lines and decidual cells in tissue sections of human placenta. Screening of 160 mammary adenocarcinomas demonstrated significant immunoreactivity in only four tumours, indicating that PRLR is generally not strongly upregulated in human breast cancer. However, even a very low level of PRLR expression was found to be sufficient to mediate PRL responsiveness in breast cancer cell lines.

This article has been cited by other articles:

				A. Q. Reuwer, M. T. Twickler, B. A. Hutten, F. W. Molema, N. J. Wareham, G. M. Dallinga-Thie, R. L. Bogorad, V. Goffin, M. Smink-Bol, J. J.P. Kastelein, et al. Prolactin Levels and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women Circ Cardiovasc Genet, August 1, 2009; 2(4): 389 - 395. [Abstract] [Full Text] [PDF]